Ankeet Bhatt
Cardiovascular Disease · Durham, NCNPI 1952797581
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $173,153 of the $257,615 with a category attached, or 67.2%. 18 manufacturers reported payments, led by Novo Nordisk at 24.2% of the total. 2025 is the largest year on record at $137,609, more than ten times the $1,001 reported in 2019. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $1764.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$62K
- Sanofi Pasteur Inc.$50K
- Eko Health, Inc.$48K
- AstraZeneca$28K
- Bayer$21K
- Amgen$19K
- plus $29K from 12 others
Across 1 payment — averaging $310.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$311
What the payments were for
- Consulting fees$173,15367%
- Speaking & faculty fees$25,06910%
- Travel & lodging$54,07021%
- Food & beverage$4,5122%
- Education$3630%
- Other$4490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $62,469 |
| Sanofi Pasteur Inc. | 20 | $50,094 |
| Eko Health, Inc. | 3 | $47,923 |
| AstraZeneca | 33 | $27,811 |
| Bayer | 22 | $21,301 |
| Amgen | 12 | $19,372 |
| Esperion Therapeutics, Inc. | 4 | $13,200 |
| Merck | 11 | $11,698 |
| Altathera Pharmaceuticals LLC | 2 | $1,763 |
| Boehringer Ingelheim | 1 | $1,043 |
| Astellas Pharma US Inc | 4 | $363 |
| Astrazeneca UK Limited | 3 | $207 |
| Daxor Corporation | 2 | $99 |
| Novartis | 1 | $94 |
| Johnson & Johnson | 1 | $93 |
| Endotronix, Inc. | 1 | $50 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Cvrx, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$20,803
- Repatha$19,043
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$15,527
- NEXLIZET$13,200
- NEXLETOL$13,200
- LOKELMA$12,721
- Sotalol Hydrochloride$1,750
- JARDIANCE$1,043
- NO PRODUCT DISCUSSED$809
How this compares
$257,615 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 13 | $130 |
| Diltiazem Hcl | 12 | $130 |
| Ezetimibe | 12 | $103 |
| Metoprolol Succinate | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Christopher GrangerDurham$257K
- Gary FelkerDurham$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.